Trials / Active Not Recruiting
Active Not RecruitingNCT06859294
A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
A Phase 2a, Single-Arm Study to Investigate the Efficacy and Safety of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week screening period, 24-week treatment period, and a 20-week safety follow up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3541860 | Administered IV |
Timeline
- Start date
- 2025-03-19
- Primary completion
- 2025-11-10
- Completion
- 2026-09-01
- First posted
- 2025-03-05
- Last updated
- 2026-01-20
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06859294. Inclusion in this directory is not an endorsement.